Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 5Neoplasms 3Recurrence 1Neoplasm Metastasis 1Melanoma 1Glioblastoma 1Carcinoma, Medullary 1

Interventions

vandetanib 9cabozantinib 6selpercatinib 4Sorafenib 3Sunitinib 2Magnetic Resonance Spectroscopy 2yeast-CEA vaccine 1tanespimycin 1rovalpituzumab tesirine 1pralsetinib 1pembrolizumab 1pazopanib 1lenvatinib 1Vorinostat 1Temozolomide 1Specimen Handling 1Pharmacogenomic Testing 1Nivolumab 1Lithium Carbonate 1Irinotecan 1Gefitinib 1Ferrosoferric Oxide 1Dexamethasone 1Capecitabine 1Bortezomib 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Medullary × rovalpituzumab tesirine × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡